Hermann Martina, Poslussny Jelena, Gerger Gernot, Haslacher Helmuth, Mayrhofer Georg, Tretter Verena Eva, Maleczek Mathias, Ekmekcioglu Cem
Medical University of Vienna, Department of Anaesthesia, Intensive Care Medicine and Pain Medicine, Clinical Division of General Anaesthesia and Intensive Care Medicine, 1090 Vienna, Austria.
Ludwig Boltzmann Institute for Digital Health and Patient Safety, 1090 Vienna, Austria.
Medicina (Kaunas). 2025 May 16;61(5):901. doi: 10.3390/medicina61050901.
: Therapeutic interventions, such as extracorporeal membrane oxygenation (ECMO) therapy, in patients suffering from severe acute respiratory distress syndrome (ARDS) may reduce their vitamin D levels. Many observational studies have shown associations between poor outcomes and low vitamin D levels in critically ill patients. This retrospective study primarily aimed to investigate the time-dependent changes in vitamin D levels and the correlation of vitamin D levels with disease severity and inflammatory markers in patients suffering from ARDS receiving ECMO therapy. : This study used a longitudinal approach to assess the serial changes and the correlations of vitamin D levels (25-hydroxyvitamin D (25(OH)D) and 1,25-dihydroxyvitamin D (1,25(OH)2D)) with disease severity and inflammatory markers in 24 invasively mechanically ventilated (IMV) patients treated using ECMO over a period of 17 days. Most of the patients in this study were suffering from severe coronavirus disease 2019 (COVID-19) ( = 19; 79%). Serial blood samples collected during routine blood draws were retrospectively analyzed to assess the dynamics of their vitamin D levels over 17 days of ICU therapy. : Hypovitaminosis D (25(OH)D ≤ 50 nmol/L) was prevalent in 18 (75%) patients, while values of 25(OH)D lower than 30 nmol/L were measured in 5 patients (21%), indicating severe deficiency. Additionally, 1,25(OH)2D showed a significant decrease within the first 11 days of intensive care unit (ICU) treatment (these levels dropped by 28%; = 0.03) and then remained at similar levels throughout the observational period; 25(OH)D levels remained largely unchanged during the observation period. We observed that 25(OH)D showed a significant negative correlation with C-reactive protein (CRP) ( = 0.04), and that 25(OH)D and 1,25(OH)2D levels did not show correlations with disease severity. : Patients suffering from severe COVID-19 ARDS showed a significant decrease in their 1,25(OH)2D levels from day 0 to day 11 in the ICU. Therefore, routine vitamin D substitution and monitoring in critically ill patients, especially for patients suffering from ARDS treated with ECMO, should be carried out to prevent hypovitaminosis D. In addition, vitamin D may be associated with inflammation. Further studies are necessary to elucidate the mechanisms behind these retrospective observations.
对于患有严重急性呼吸窘迫综合征(ARDS)的患者,诸如体外膜肺氧合(ECMO)治疗等治疗干预措施可能会降低其维生素D水平。许多观察性研究表明,重症患者预后不良与维生素D水平低之间存在关联。这项回顾性研究主要旨在调查接受ECMO治疗的ARDS患者维生素D水平随时间的变化,以及维生素D水平与疾病严重程度和炎症标志物之间的相关性。
本研究采用纵向研究方法,评估了24例接受有创机械通气(IMV)并使用ECMO治疗17天的患者维生素D水平(25-羟基维生素D(25(OH)D)和1,25-二羟基维生素D(1,25(OH)2D))的系列变化及其与疾病严重程度和炎症标志物的相关性。本研究中的大多数患者患有严重的2019冠状病毒病(COVID-19)(n = 19;79%)。对常规采血期间采集的系列血样进行回顾性分析,以评估其在重症监护病房(ICU)治疗17天期间维生素D水平的动态变化。
维生素D缺乏症(25(OH)D≤50 nmol/L)在18例(75%)患者中普遍存在,而5例患者(21%)的25(OH)D值低于30 nmol/L,表明存在严重缺乏。此外,1,25(OH)2D在重症监护病房(ICU)治疗的前11天内显著下降(这些水平下降了28%;P = 0.03),然后在整个观察期内保持在相似水平;25(OH)D水平在观察期内基本保持不变。我们观察到25(OH)D与C反应蛋白(CRP)呈显著负相关(P = 0.04),并且25(OH)D和1,25(OH)2D水平与疾病严重程度无相关性。
患有严重COVID-19 ARDS的患者在ICU中从第0天到第11天其1,25(OH)2D水平显著下降。因此,应对重症患者,尤其是接受ECMO治疗的ARDS患者进行常规维生素D替代和监测,以预防维生素D缺乏症。此外,维生素D可能与炎症有关。需要进一步研究以阐明这些回顾性观察结果背后的机制。